Skip to main content
NewslettersWatchlist

Scholar Rock Holding Corp(SRRK-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low9.37
Day High9.95
Open:9.81
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
S&P 500 Posts a Record High on Optimism the Fed Can Achieve a Soft Landing
Barchart
Stocks Pressured by Hawkish Statement by a Fed Official
Barchart
Stocks See Support from Improved Soft-Landing Prospects
Motley Fool
Why Scholar Rock Holding Stock Soared Today
Business Wire
Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference
Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors
Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
Business Wire
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Business Wire
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference
Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer
Business Wire
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023
Business Wire
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference
Business Wire
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
Business Wire
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
Business Wire
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
Business Wire
Scholar Rock to Participate in Upcoming Investor Conferences
Business Wire
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
Business Wire
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting
Business Wire
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
Business Wire
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
Business Wire
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
Business Wire
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
Business Wire
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
Business Wire
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference
Business Wire
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFฮฒ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
Business Wire
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
Motley Fool
Why Scholar Rock Stock Flew High Today

Profile

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.